European Biophysics Journal

, 39:201 | Cite as

On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the “space–time” dimension of MDR

  • Vasiliki Panagiotopoulou
  • Giles Richardson
  • Oliver E. Jensen
  • Cyril Rauch
Review

Abstract

Multidrug resistance (MDR) is explained by drug transporters with a drug-handling activity. Despite much work, MDR remains multifaceted, and several conditions are required to generate drug resistance. The drug pumping was conceptually described using a kinetic, i.e., temporal, approach. The re-emergence of physical biology has allowed us to take into account new parameters focusing on the notion of space. This, in turn, has given us important clues regarding the process whereby drug and transporter interact. We will demonstrate that the likelihood of drug-transporter meeting (i.e., the affinity) and thus interaction are also driven by the mechanical interaction between drug molecular weight (MW) and the membrane mechanical properties. This should allow us to mechanically control drug delivery.

Keywords

Physical biology Pharmacokinetic Membrane Drug delivery Multi-drug resistance Lipinski’s second rule 

References

  1. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–1722CrossRefPubMedGoogle Scholar
  2. Ambudkar SV, Kim IW, Sauna ZE (2006) The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 27:392–400CrossRefPubMedGoogle Scholar
  3. Ayrton A, Morgan P (2008) Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 38:676–708CrossRefPubMedGoogle Scholar
  4. Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174–1184PubMedGoogle Scholar
  5. Borgnia MJ, Eytan GD, Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163–3171CrossRefPubMedGoogle Scholar
  6. Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537–592CrossRefPubMedGoogle Scholar
  7. Buxbaum E (1999) Co-operating ATP sites in the multiple drug resistance transporter Mdr1. Eur J Biochem 265:54–63CrossRefPubMedGoogle Scholar
  8. Chan LM, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25–51CrossRefPubMedGoogle Scholar
  9. Chang XB (2007) A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev 26:15–37CrossRefPubMedGoogle Scholar
  10. Dano K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466–483CrossRefPubMedGoogle Scholar
  11. Devaux PF (2000) Is lipid translocation involved during endo and exocytosis? Biochimie 82:497–509CrossRefPubMedGoogle Scholar
  12. Drews J (2003) Strategic trends in the drug industry. Drug Discov Today 8:411–420CrossRefPubMedGoogle Scholar
  13. Eytan GD, Regev R, Oren G, Hurwitz CD, Assaraf YG (1997) Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 248:104–112CrossRefPubMedGoogle Scholar
  14. Farge E (1995) Increased vesicle endocytosis due to an increase in the plasma membrane phosphatidylserine concentration. Biophys J 69:2501–2506CrossRefPubMedGoogle Scholar
  15. Farge E, Devaux PF (1992) Shape changes of giant liposomes induced by an asymmetric transmembrane distribution of phospholipids. Biophys J 61:347–357CrossRefPubMedGoogle Scholar
  16. Farge E, Bitbol M, Devaux PF (1990) Biomembrane elastic response to intercalation of amphiphiles. Eur Biophys J 19:69–72CrossRefPubMedGoogle Scholar
  17. Farge E, Ojcius DM, Subtil A, Dautry-Varsat A (1999) Enhancement of endocytosis due to aminophospholipid transport across the plasma membrane of living cells. Am J Physiol 276:C725–C733PubMedGoogle Scholar
  18. Fromm MF (2003) Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33(Suppl 2):6–9CrossRefPubMedGoogle Scholar
  19. Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51:817–834CrossRefPubMedGoogle Scholar
  20. Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS (2004) Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J Pharm Sci 93:957–968CrossRefPubMedGoogle Scholar
  21. Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749–757CrossRefPubMedGoogle Scholar
  22. Hochmuth FM, Shao JY, Dai J, Sheetz MP (1996) Deformation and flow of membrane into tethers extracted from neuronal growth cones. Biophys J 70:358–369CrossRefPubMedGoogle Scholar
  23. Hou TJ, Xu XJ (2003) ADME evaluation in drug discovery. 3. Modeling blood–brain barrier partitioning using simple molecular descriptors. J Chem Inf Comput Sci 43:2137–2152PubMedGoogle Scholar
  24. Israelachvili JN, Marcelja S, Horn RG (1980) Physical principles of membrane organization. Q Rev Biophys 13:121–200CrossRefPubMedGoogle Scholar
  25. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162CrossRefPubMedGoogle Scholar
  26. Kim H, Barroso M, Samanta R, Greenberger L, Sztul E (1997) Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. Am J Physiol 273:C687–C702PubMedGoogle Scholar
  27. Kimura Y, Morita SY, Matsuo M, Ueda K (2007) Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 98:1303–1310CrossRefPubMedGoogle Scholar
  28. Koval M, Pagano RE (1991) Intracellular transport and metabolism of sphingomyelin. Biochim Biophys Acta 1082:113–125PubMedGoogle Scholar
  29. Lange Y, Swaisgood MH, Ramos BV, Steck TL (1989) Plasma membranes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts. J Biol Chem 264:3786–3793PubMedGoogle Scholar
  30. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26CrossRefPubMedGoogle Scholar
  31. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R (2000a) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624–632PubMedGoogle Scholar
  32. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R (2000b) Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 39:11901–11906CrossRefPubMedGoogle Scholar
  33. Martin C, Higgins CF, Callaghan R (2001) The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein. Biochemistry 40:15733–15742CrossRefPubMedGoogle Scholar
  34. Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081–3091CrossRefPubMedGoogle Scholar
  35. Oprea TI (2002) Current trends in lead discovery: are we looking for the appropriate properties? Mol Divers 5:199–208CrossRefPubMedGoogle Scholar
  36. Palm K, Stenberg P, Luthman K, Artursson P (1997) Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 14:568–571CrossRefPubMedGoogle Scholar
  37. Proudfoot JR (2002) Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg Med Chem Lett 12:1647–1650CrossRefPubMedGoogle Scholar
  38. Quinn RJ, Carroll AR, Pham NB, Baron P, Palframan ME, Suraweera L, Pierens GK, Muresan S (2008) Developing a drug-like natural product library. J Nat Prod 71:464–468CrossRefPubMedGoogle Scholar
  39. Rauch C (2009a) On the relationship between drug’s size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data. Eur Biophys J 38:537–546CrossRefPubMedGoogle Scholar
  40. Rauch C (2009b) Toward a mechanical control of drug delivery. On the relationship between Lipinski’s 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data. Eur Biophys J 38:829–846CrossRefPubMedGoogle Scholar
  41. Rauch C, Farge E (2000) Endocytosis switch controlled by transmembrane osmotic pressure and phospholipid number asymmetry. Biophys J 78:3036–3047CrossRefPubMedGoogle Scholar
  42. Rauch C, Pluen A (2007) Multi drug resistance-dependent “vacuum cleaner” functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density. Eur Biophys J 36:121–131CrossRefPubMedGoogle Scholar
  43. Raucher D, Sheetz MP (1999) Characteristics of a membrane reservoir buffering membrane tension. Biophys J 77:1992–2002CrossRefPubMedGoogle Scholar
  44. Regev R, Eytan GD (1997) Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem Pharmacol 54:1151–1158CrossRefPubMedGoogle Scholar
  45. Roepe PD (1998) The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 166:71–73CrossRefPubMedGoogle Scholar
  46. Roepe PD, Martiney JA (1999) Are ion-exchange processes central to understanding drug-resistance phenomena? Trends Pharmacol Sci 20:62–65CrossRefPubMedGoogle Scholar
  47. Roepe PD, Wei LY, Cruz J, Carlson D (1993) Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 32:11042–11056CrossRefPubMedGoogle Scholar
  48. Roepe PD, Wei LY, Hoffman MM, Fritz F (1996) Altered drug translocation mediated by the MDR protein: direct, indirect, or both? J Bioenerg Biomembr 28:541–555CrossRefPubMedGoogle Scholar
  49. Romsicki Y, Sharom FJ (1998) The ATPase and ATP-binding functions of P-glycoprotein—modulation by interaction with defined phospholipids. Eur J Biochem 256:170–178CrossRefPubMedGoogle Scholar
  50. Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, Higgins CF (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 20:5615–5625CrossRefPubMedGoogle Scholar
  51. Rudnick J, Gaspari G (2004) Elements of random walk. Cambridge University Press, CambridgeGoogle Scholar
  52. Santai CT, Fritz F, Roepe PD (1999) Effects of ion gradients on H+ transport mediated by human MDR 1 protein. Biochemistry 38:4227–4234CrossRefPubMedGoogle Scholar
  53. Sauna ZE, Ambudkar SV (2000) Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci USA 97:2515–2520CrossRefPubMedGoogle Scholar
  54. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev 36:179–194CrossRefPubMedGoogle Scholar
  55. Sehested M, Skovsgaard T, van Deurs B, Winther-Nielsen H (1987a) Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites tumor cell lines. J Natl Cancer Inst 78:171–179PubMedGoogle Scholar
  56. Sehested M, Skovsgaard T, van Deurs B, Winther-Nielsen H (1987b) Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br J Cancer 56:747–751PubMedGoogle Scholar
  57. Seifert U, Berndl K, Lipowsky R (1991) Shape transformations of vesicles: phase diagram for spontaneous-curvature and bilayer-coupling models. Phys Rev A 44:1182–1202CrossRefPubMedGoogle Scholar
  58. Seigneuret M, Devaux PF (1984) ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes. Proc Natl Acad Sci USA 81:3751–3755CrossRefPubMedGoogle Scholar
  59. Seigneuret M, Zachowski A, Hermann A, Devaux PF (1984) Asymmetric lipid fluidity in human erythrocyte membrane: new spin-label evidence. Biochemistry 23:4271–4275CrossRefPubMedGoogle Scholar
  60. Shapiro AB, Ling V (1995) Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 270:16167–16175CrossRefPubMedGoogle Scholar
  61. Shapiro AB, Ling V (1997) Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. Eur J Biochem 250:122–129CrossRefPubMedGoogle Scholar
  62. Shapiro AB, Corder AB, Ling V (1997) P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 250:115–121CrossRefPubMedGoogle Scholar
  63. Sharom FJ, Lugo MR, Eckford PD (2005) New insights into the drug binding, transport and lipid flippase activities of the p-glycoprotein multidrug transporter. J Bioenerg Biomembr 37:481–487CrossRefPubMedGoogle Scholar
  64. Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S, van Veen HW (2006) New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci 27:195–203CrossRefPubMedGoogle Scholar
  65. Simon S (2001) The multiple mechanisms of multidrug resistance and cellular pH. Novartis Found Symp 240:269–281 (discussion 282–9)CrossRefPubMedGoogle Scholar
  66. Simon S, Roy D, Schindler M (1994) Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 91:1128–1132CrossRefPubMedGoogle Scholar
  67. van Meer G (1989) Lipid traffic in animal cells. Annu Rev Cell Biol 5:247–275CrossRefPubMedGoogle Scholar
  68. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623CrossRefPubMedGoogle Scholar
  69. Walker JE, Saraste M, Runswick MJ, Gay NJ (1982) Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1:945–951PubMedGoogle Scholar
  70. Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159–168CrossRefPubMedGoogle Scholar

Copyright information

© European Biophysical Societies' Association 2009

Authors and Affiliations

  • Vasiliki Panagiotopoulou
    • 1
  • Giles Richardson
    • 2
  • Oliver E. Jensen
    • 1
  • Cyril Rauch
    • 3
  1. 1.School of Mathematical SciencesUniversity of NottinghamNottinghamUK
  2. 2.School of MathematicsUniversity of SouthamptonSouthamptonUK
  3. 3.School of Veterinary Medicine and ScienceUniversity of NottinghamSutton BoningtonUK

Personalised recommendations